Drug Trial Radar · NCT03738917
Effectiveness of Antitussives, Anticholinergics and Honey Versus Usual Care in Adults With Acute Bronchitis.
Last checked: Nov 19, 2026Latest source record: Aug 30, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
668
Actual
Start
Feb 1, 2019
Primary completion
Nov 30, 2021
Study completion Dec 31, 2021
Sponsor
- Lead sponsor
- Fundacio d'Investigacio en Atencio Primaria Jordi Gol i GurinaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Spanish Clinical Research Network - SCReN
- First posted
- Nov 13, 2018
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study, which is aimed at comparing the effectiveness of 3 symptomatic therapies (dextromethorphan, ipratropium and honey) associated with usual care and the usual care in adults with acute bronchitis, is a multicentre, pragmatic, parallel group, open randomised trial. Patients aged 18 or over with uncomplicated acute bronchitis, with cough \<3 weeks as the main symptom, scoring ≥ 4 in either daytime or nocturnal cough on a 7-point Likert scale, will be randomised to one of the 4 groups. Sample: 668 patients. The primary outcome will be the number of days with moderate-severe cough.
Conditions
- Acute Bronchitis
Interventions
Dextromethorphan 15 milligramsDrug
This drug is already marketed, and therefore, the manufacturer is responsible for the elaboration and control of samples. This study drug will be provided free to the participants by the sponsor.
Ipratropium Bromide 20Micrograms InhalerDrug
This drug is already marketed, and therefore, the manufacturer is responsible for the elaboration and control of samples. This study drug will be provided free to the participants by the sponsor.
Honey 30 g (full tablespoon)Dietary supplement
This study product will be provided free to the participants by the sponsor.
Usual clinical practiceOther
Clinicians will not be allowed to prescribe antitussives, including codeine, anticholinergic inhalers and they will not be allowed to recommend the use of honey.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Duration of moderate-severe cough in days in the four arms.Time frame: Day 29.
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Nova Lloreda Health Center
Badalona, Catalonia, Spain
Martí i Julià Health Center
Badalona, Catalonia, Spain
Balaguer Health Center
Balaguer, Catalonia, Spain
Via Roma Health Centre
Barcelona, Catalonia, Spain
La Marina Health Center
Barcelona, Catalonia, Spain
CAP Passeig Maragall (EAP Camp de l'Arpa)
Barcelona, Catalonia, Spain
Cornellà - La Gavarra Health Center
Cornellà de Llobregat, Catalonia, Spain
Pineda de Mar Health Center
Pineda de Mar, Catalonia, Spain
Ca n'OriacHealth Center
Sabadell, Catalonia, Spain
Molí Nou Health Center
Sant Boi de Llobregat, Catalonia, Spain
Singuerlin Health Center
Santa Coloma de Gramenet, Catalonia, Spain
CAP Jaume I
Tarragona, Catalonia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.